Stephanie Flaspoehler
Adult Health · Louisville, KYNPI 1659368744
Payments from drug & device makers
Across 972 payments — averaging $179.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$172K
- Teleflex LLC$511
- Astellas Pharma US Inc$286
- Endo Pharmaceuticals Inc.$258
- Boston Scientific$221
- Amgen$160
- plus $1K from 20 others
Across 2 payments — averaging $140.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$280
What the payments were for
- Consulting fees$4500%
- Speaking & faculty fees$115,66466%
- Travel & lodging$42,10624%
- Food & beverage$15,5809%
- Education$3440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 865 | $171,565 |
| Teleflex LLC | 13 | $511 |
| Astellas Pharma US Inc | 11 | $286 |
| Endo Pharmaceuticals Inc. | 13 | $258 |
| Boston Scientific | 6 | $221 |
| Amgen | 8 | $160 |
| Johnson & Johnson | 6 | $147 |
| Urovant Sciences Inc | 7 | $132 |
| Antares Pharma, Inc. | 7 | $125 |
| Axonics, Inc. | 5 | $124 |
| AbbVie | 6 | $99 |
| Merck | 4 | $74 |
| Clarus Therapeutics Inc. | 4 | $65 |
| Urogen Pharma, Inc. | 1 | $64 |
| Myovant Sciences Inc. | 2 | $42 |
| Accord Healthcare, Inc. | 2 | $39 |
| AstraZeneca | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Tolmar, Inc. | 1 | $28 |
| Novartis | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Acacia Pharma Inc | 1 | $16 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$153,292
- UroLift System$377
- PERCEPT PC BRAINSENSE$267
- AdVance XP$136
How this compares
$174,144 in reported general payments places this provider in the 95th percentile of 170 adult health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 112 | $92,693 |
| MyrbetriqMirabegron | 113 | $87,734 |
| Mirabegron ErMirabegron | 23 | $20,996 |
| ElmironPentosan Polysulfate Sodium | 13 | $14,182 |
| Estradiol | 186 | $10,063 |
| Methenamine Hippurate | 56 | $6,016 |
| Trospium Chloride | 42 | $3,183 |
| Trospium Chloride ErTrospium Chloride | 11 | $1,644 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 102 | $1,471 |
| Solifenacin Succinate | 17 | $928 |
| Tamsulosin Hcl | 41 | $525 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $487 |
| Metronidazole | 39 | $461 |
| Terconazole | 15 | $404 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $92,693112 claims |
| Astellas Pharma US IncMyrbetriq | $286 | $87,734113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 adult health providers in Kentucky.
Other adult health in Louisville
- Heidi GalloLouisville$15K
- Karen EastridgeLouisville$10K
- Barbara CarpenterLouisville$8K
- Loren GarzaLouisville$6K
- Kelly MikeLouisville$4K
- Layla Al-ShamiLouisville$3K
- Brittany McWhorterLouisville$3K
- Lahoma PratherLouisville$2K
- William NapierLouisville$2K
- Barbara LemmonsLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.